Next Article in Journal
The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
Previous Article in Journal
Current Debates in the Management of Visceral Artery Aneurysms: Where the Guidelines Collide
Previous Article in Special Issue
Comment on Moshirfar et al. Accuracy of Six Intraocular Lens Power Calculations in Eyes with Axial Lengths Greater than 28.0 mm. J. Clin. Med. 2022, 11, 5947
 
 
Reply
Peer-Review Record

Reply to Cione et al. Comment on “Moshirfar et al. Accuracy of Six Intraocular Lens Power Calculations in Eyes with Axial Lengths Greater than 28.0 mm. J. Clin. Med. 2022, 11, 5947”

by Majid Moshirfar 1,2,3,*, Kathryn M. Durnford 4, Jenna L. Jensen 4, Daniel P. Beesley 5, Telyn S. Peterson 6, Ines M. Darquea 1, Yasmyne Castillo Ronquillo 1 and Phillip C. Hoopes 1
Reviewer 1: Anonymous
Reviewer 2:
Submission received: 9 February 2023 / Accepted: 20 March 2023 / Published: 4 May 2023
(This article belongs to the Special Issue Current Challenges and Advances in Cataract Surgery)

Round 1

Reviewer 1 Report

Answers are appropiated

Reviewer 2 Report

Responses seem fine to me. 

Back to TopTop